PainReform (NASDAQ:PRFX) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of PainReform (NASDAQ:PRFX) to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

PainReform Price Performance

Shares of NASDAQ PRFX opened at $1.00 on Friday. PainReform has a 1-year low of $0.97 and a 1-year high of $17.95. The business has a fifty day moving average price of $1.46 and a 200 day moving average price of $2.31. The stock has a market capitalization of $870,000.00, a P/E ratio of -0.00 and a beta of 1.05.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.